AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jia Fan, Zhenggang Ren, Chiun Hsu, Yabing Guo, Tianqiang Song, Wentao Wang, Yee Chao, Yujuan Gao, Bai Li, Salvatore Ferro, Chia-Jui Yen
Institutions: Fudan University, Zhongshan Hospital, National Taiwan University Hospital, Nanfang Hospital, Southern Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Sichuan University, West China Hospital of Sichuan University, Taipei Veterans General Hospital, BeiGene (China), National Cheng Kung University Hospital
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4205775339